Ticagrelor for Inflammation and Cardiovascular Risk in Patients With Chronic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 230 participants.

Also called NCT07911124

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 230 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07911124
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07911124. Randomized; quadruple masking; primary purpose treatment. Start 2026-11 (anticipated); primary completion 2030-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ticagrelor for Inflammation and Cardiovascular Risk in Patients With Chronic Kidney Disease
Acronym
TACTIC-CKD
Intervention (Drug)
Ticagrelor: an oral, direct-acting, reversibly binding P2Y12 receptor antagonist
Intervention (Drug)
Placebo
Lead sponsor
University of Arkansas (class: other)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct07911124
Content hash
681cee249588c530b6581120c85e0718b21d6bb4a6fc03e8ed56df91d0481d22